Allergy/Imm Medical News about cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Tumour-derived prostaglandin E2 and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha
Immunology, 10/13/09

Bekeredjian–Ding I et al. – In previous studies the authors reported that plasmacytoid dendritic cells (PDC) infiltrating head and neck cancer tissue are functionally impaired, but the molecular basis for the functional deficiency remained unclear. In TLR–stimulated PDC, PGE2 and TGF–beta reduce the CCR7 : CXCR4 ratio, suggesting that PDC are impaired in their ability to migrate to tumour–draining lymph nodes but are retained in stromal cell–derived factor 1 (SDF–1)–expressing tissues. Based on these data, cyclooxygenase inhibitors and TGF–beta antagonists may improve TLR7– and TLR9–based tumour immunotherapy.

<< Previous
Ex vivo expanded cord blood CD4 T lymphocytes exhibit a distinct...

Next >>
Differences in physicians self-reported knowledge of, attitudes...